Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Cognitive Dysfunction × Methylphenidate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fatigue 14 Neoplasms 6 Brain Neoplasms 5 Prostatic Neoplasms 4 Depression 4 Sleep Wake Disorders 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Central Nervous System Neoplasms 2 Breast Neoplasms 2 Asthenia 2 Recurrence 1 Oligodendroglioma 1 Neurotoxicity Syndromes 1 Neurofibromatosis 1 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Meningioma 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma, Subependymal 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Ependymoma 1 Cognitive Dysfunction 1 Astrocytoma 1 Anxiety Disorders 1

Interventions

Exercise 6 Transcranial Direct Current Stimulation 4 Neuropsychological Tests 4 Walking 3 Memantine 3 Tablets 2 Standard of Care 2 Patient Reported Outcome Measures 2 Methods 2 Electroencephalography 2 Donepezil 2 Cognitive Behavioral Therapy 2 mazdutide 1 lime 1 enzalutamide 1 blueberry extract 1 beta Carotene 1 acetaminophen, aspirin, caffeine drug combination 1 Waiting Lists 1 Vitamin E 1 Vitamin D 1 Ultraviolet Therapy 1 Time 1 Tai Ji 1 Surveys and Questionnaires 1 Sugars 1 Sodium Chloride 1 Sirolimus 1 Riluzole 1 Rehabilitation, Vocational 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡